Currently, the use of endogenous NP therapeutic with sacubitril/valsartan is a class I recommendation for HF with reduced EF as a replacement for an ACE inhibitor or angiotensin receptor blocker [68]. This evidence concerns the gene ACE and hydrops fetalis.